Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADP-TILIL7 · 1 trial · 3 indications
Fraction of subjects experiencing grade \>/= 3 AE
Measured by the number of subjects who undergo surgery and succesfully undergo ADP-TILIL7-infusion
| Arm | Type | Description |
|---|---|---|
| Tumor-infiltrating lymphocytes genemodified with IL-7 gene for IL-7 production upon Ag engagement | EXPERIMENTAL | Tumor-infiltrating lymphocytes grown ex-vivo from resected tumor tissue and reapplied to the patient via an intravenous infusion. Drug: Cyclophosphamide: 2 doses (69 mg/kg) prior to infusion Drug: Fludarabinephosphat 5 doses (25 mg/m2, max. 50 mg) prior to infusion Drug: Proleukin 600.000 IU/kg/dose IL-2 a maximum of 6 doses |
| Name | Type | Description |
|---|---|---|
| ADP-TILIL7 | BIOLOGICAL | Autologous tumor infiltrating lymphocytes genemodified (by a lentiviral vector) to produce IL-7 upon antigen engagement |
| Cyclophosphamide | DRUG | Lymphodepleting Chemotherapy |
| Fludarabine Phosphate | DRUG | Lymphodepleting Chemotherapy |
| Proleukin | DRUG | IL-2 |
Inclusion Criteria: * All the criteria listed in the following need to be met before patient inclusion. 1. Histologically confirmed inoperable or metastatic melanoma (stage IIIc or IV). 2. Progressive disease after standard treatment with PD-1 check-point inhibition or combination of aforement...
ADP-TILIL7 is an investigational monoclonal antibody being studied for the treatment of melanoma, specifically in patients with Stage III and Stage IV melanoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ADP-TILIL7 is being developed by Adaptimmune Therapeutics PLC, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ADAP. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of this investigational therapy.
ADP-TILIL7 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is currently recruiting participants to assess its safety and efficacy.
ADP-TILIL7 is being studied in a single Phase 1 clinical trial with the identifier NCT06204991. This trial is evaluating the safety and efficacy of ADP-TILIL7 in patients with locally advanced or metastatic melanoma, including Stage III and Stage IV disease. The trial is currently recruiting participants in Denmark.
No alternative names for ADP-TILIL7 have been disclosed. It is a distinct investigational monoclonal antibody being developed by Adaptimmune Therapeutics for the treatment of melanoma. No other drug names have been associated with this asset in the available information.